Beta Bionics proposes to offer $125,000,000 of common stock and has granted underwriters a 30-day option for up to $18,750,000 more. Proceeds may support Mint commercialization, Manufacturing expansion, research and clinical development, product enhancements, strategic opportunities, Working Capital and operating expenses.

Key Highlights

  • The share-count framework starts with 44,981,606 common shares outstanding before accounting for specified Equity awards and plan reserves.
  • Beta Bionics is authorized to issue 700,000,000 common shares and 10,000,000 preferred shares.
  • Beta Bionics plans to offer $125,000,000 of common stock in a proposed public sale.
  • Underwriters would have 30 days to purchase up to an additional $18,750,000 of common stock.

Beta Bionics, Inc. (NASDAQ: BBNX) plans to offer $125,000,000 of common stock in a proposed public sale. Underwriters would have 30 days to buy up to an additional $18,750,000 of common stock, giving the transaction a potential larger size if that option is fully exercised. The company says the net proceeds may fund Mint commercialization, manufacturing-facility expansion, research and clinical development, product enhancements, strategic opportunities, working capital and operating expenses.

Common Stock Sale Includes Upsize Option

The shares carry a Par Value of $0.0001 each and are listed on the Nasdaq Global Market under BBNX. The post-offering share-count calculation is based on 44,981,606 common shares outstanding as of June 30, 2026. The calculation also excludes 9,365,787 shares authorized for future issuance under the 2025 Equity Incentive Plan and 761,403 shares reserved under the 2025 Employee Stock Purchase Plan.

Proceeds May Support Mint Development

Beta Bionics retains broad discretion over the use of proceeds, with the stated purposes spanning product development, operations and potential strategic opportunities. The common stock’s last reported sale price was $16.73 per share on September 14, 2026. Historical net tangible Book Value stood at $5.70 per share as of June 30, 2026. The company’s amended and restated certificate of incorporation authorizes 700,000,000 common shares and 10,000,000 preferred shares.